Core Insights - Calidi Biotherapeutics has announced the acceptance of its abstract for presentation at the AACR Annual Meeting, highlighting its commitment to advancing systemic enveloped virotherapy for metastatic cancers [1][2] - The proprietary RTNova systemic platform aims to address challenges in treating advanced-stage metastatic cancers by enabling targeted delivery to multiple tumor sites while evading rapid elimination by the immune system [2][3] - The company is also preparing to submit an abstract for the ASCO Annual Meeting in June 2025, focusing on selecting a lead clinical candidate for RTNova [4] Company Overview - Calidi Biotherapeutics is a clinical-stage immuno-oncology company that utilizes proprietary technology to enhance the immune system's ability to combat cancer [5] - The company employs novel stem cell-based platforms that can carry oncolytic viruses for various oncology indications, including high-grade gliomas and solid tumors [5] - Calidi's dual approach includes both systemic enveloped virotherapies and localized cell-based virotherapies, aiming to treat or prevent metastatic disease [5]
Calidi Biotherapeutics Announces Presentation of New Data of Systemic Virotherapy RTNova Platform at the AACR Annual Meeting in April 2025